Jundishapur J Microbiol
Jundishapur J Microbiol

article information

Jundishapur Journal of Microbiology: Vol.15, issue 1; e122074
published online: February 19, 2022
article type: Case Report
received: December 27, 2021
revised: February 5, 2022
accepted: February 5, 2022
DOI: https://doi.org/10.5812/jjm.122074
Crossmark

Upper Limb Ischemia Following COVID-19 Infection: A Case Report

authors:

avatar Mohsen Arabi 1 , avatar Hazhir Heidari Beigvand 2 , avatar HamidReza Samimagham ORCID 3 , avatar Nastaran Salimi 4 , avatar Mitra Kazemi Jahromi ORCID 5 , *

Department of Family Medicine, Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran
Firoozabadi Research Development Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
Clinical Research Development Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

how to cite: Arabi M, Heidari Beigvand H, Samimagham H, Salimi N, Kazemi Jahromi M. Upper Limb Ischemia Following COVID-19 Infection: A Case Report. Jundishapur J Microbiol. 2022;15(1):e122074. https://doi.org/10.5812/jjm.122074.

Abstract

Introduction:

COVID-19 infection can cause a wide range of complications, from respiratory infection to skin rashes.

Case Presentation:

Here, we report a case of a 73-year-old woman with left brachial artery thrombosis 2 weeks after the onset of COVID-19 infection, leading to left upper limb ischemia.

Conclusions:

Given the life-changing nature of limb ischemia that can lead to amputation, it is crucial to consider it from the beginning of COVID-19 infection and think of preventive measures in this pandemic.

1. Introduction

COVID-19 has shocked the world not only by affecting people’s lives in many ways, but also by causing various complications from respiratory infection to skin rashes (1). The ability of the virus to hide behind the mask of various symptoms adds to the risk of leaving permanent sequels, a mystery that needs to be gradually discovered. Coagulopathy is a serious complication that occurs in 20 - 55% of the patients (2). The most common coagulopathies are respectively deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and myocardial infarction. Data about peripheral arterial events in COVID-19 are limited, and despite a number of reports on lower limb ischemia, upper limb ischemia is quite rare (3, 4). Here, we report a case of a 73-year-old woman with a history of non-insulin-dependent diabetes and hypertension who developed left brachial artery thrombosis 2 weeks after the onset of COVID-19 infection, leading to left upper limb ischemia.

2. Case Presentation

A 73-year-old woman was admitted to the emergency department of Firoozabadi Hospital on July 10, 2020, with fever, hypoxia, and loss of consciousness. According to her family, her initial symptoms (including dyspnea, fatigue, and fever) had been going on for 2 weeks, but she refused to seek medical advice earlier due to fear of the pandemic. Her past medical history included non-insulin-dependent diabetes and hypertension. She was a non-smoker and did not consume alcohol. She was transferred to the hospital by paramedics and had already received supplemental oxygen; therefore, her peripheral oxygen saturation was 90%. She was hemodynamically unstable with a blood pressure of 90/60 mm Hg and a heart rate of 90 bpm. Her body temperature was 38.1°C, and her Glasgow Coma Scale (GCS) was 10/15. The initial laboratory findings revealed leukocytosis, thrombocytosis, elevated blood urea nitrogen (BUN), creatinine, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), troponin, and C-reactive protein (CRP; see Table 1).

Table 1.

Laboratory Findings

VariablesValues
White cell count (per mm3)15400
Neutrophil (per mm3)13444
Lymphocyte (per mm3)1185
Red cell count (million per mm3)5.25
Hemoglobin (g/dL)15.2
Platelet count (per mm3)736000
Prothrombin time (s)17
International normalized ratio (index)1.5
Partial thromboplastin time (s)42
Blood glucose (mg/dL)484
BUN (mg/dL)93
Creatinine (mg/dL)3.3
Aspartate aminotransferase (U/L)42
Alanine aminotransferase (U/L)31
Lactate dehydrogenase (U/L)1485
Creatine phosphokinase (U/L)710
Alkaline phosphatase (U/L)216
Total bilirubin (mg/dL)2
Direct bilirubin (mg/dL)0.6
Serum Na (mmol/L)156
Serum K (mmol/L)2.6
Troponin (ng/L)50.7
C-reactive protein (mg/L)64.2

A chest computed tomography (CT) scan revealed diffused patchy ground-glass opacities and consolidation in both lungs (Figure 1), and she was given lopinavir/ritonavir, ceftriaxone, azithromycin, dexamethasone, enoxaparin, and paracetamol. Two weeks after the onset of symptoms (a few hours after admission to the hospital), she suddenly developed mottling in her left forearm; her left hand turned cold and pale, and there were no palpable radial and ulnar pulses. Color Doppler ultrasonography was immediately performed, reporting the absence of blood flow in the distal third of the left brachial artery, and the tardus parvus pattern in the ulnar and radial arteries suggested proximal occlusion. Her unstable condition did not allow surgical intervention to remove the thrombosis; therefore, 5000 units of heparin was administered as a stat dose and then continued at 800 units per hour. No improvements were observed. Additionally, her clinical condition deteriorated, and her respiratory failure progressed. She was intubated some hours after admission, and despite all the efforts, she passed away 72 hours after admission.

Diffuse patchy ground-glass opacities and consolidation in both lungs
Diffuse patchy ground-glass opacities and consolidation in both lungs
Figure 1.

Diffuse patchy ground-glass opacities and consolidation in both lungs

3. Discussion

There is still a great deal that we do not know about the mechanisms by which SARS-CoV-2 affects the organs. Since the beginning of the pandemic, various studies have suggested coagulopathy as a relatively common complication and reported a correlation between the severity of infection and coagulation disturbances (4). That is why an anticoagulant agent is usually added to the regimen as prophylaxis in severe cases (5). There are cases reported all around the world that develop vein thrombosis (DVT), (pulmonary thromboembolism) PTE, or ischemia despite receiving anticoagulant agents; however, some studies have reported cases of ischemia with COVID-19 infection (6, 7).

Studies have shown an association between COVID-19 infection and hypercoagulability state. Tang et al. showed that high D-dimer and fibrin degradation product levels were higher in patients who died of COVID-19 infection (8). Ischemia in a healthy non-atherosclerotic artery is rare, but it has been reported in COVID-19 infection (9-12). The incidence of acute limb ischemia in COVID-19 patients was reported to be about 0.9% (9), which is higher than that in the general population (13) and hospitalized patients with cancer (14). Therefore, this condition is important in this population. The reason why severe complications due to coagulopathy still occur despite prophylactic measurements is unknown. Life-threatening coagulopathies (such as PTE or myocardial infarction) usually occur immediately, but limb ischemia might be missed due to their lower incidence.

3.1. Conclusions

Given the life-changing nature of limb ischemia that can lead to amputation, it is crucial to consider it from the beginning of COVID-19 infection and think of preventive measures. We hope we are being able to find effective solutions for this problem in the near future.

References